These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17487295)

  • 21. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
    Ezekowitz JA; Hernandez AF; Starling RC; Yancy CW; Massie B; Hill JA; Krum H; Diaz R; Ponikowski P; Metra M; Howlett JG; Gennevois D; O'Connor CM; Califf RM; Fonarow GC
    Am Heart J; 2009 Feb; 157(2):219-28. PubMed ID: 19185628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underutilization of angiotensin converting enzyme inhibitors among heart failure patients.
    Lean QY; Shamsuddin N; Wan Ahmad WA
    Med J Malaysia; 2008 Aug; 63(3):216-21. PubMed ID: 19248693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.
    Noviasky JA
    Pharmacotherapy; 2007 May; 27(5):626-32. PubMed ID: 17461696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 26. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
    Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM
    Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The place of ACE inhibitors in the treatment of cardiac failure].
    Gurevich MA
    Klin Med (Mosk); 2004; 82(2):4-8. PubMed ID: 15106502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative management of chronic heart failure.
    Groban L; Butterworth J
    Anesth Analg; 2006 Sep; 103(3):557-75. PubMed ID: 16931661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Heart failure. Current pharmacologic treatment].
    Coma-Canella I; Castaño S; Nasarre E
    Rev Med Univ Navarra; 2005; 49(3):41-7. PubMed ID: 16400975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Turn back the tide of cardiogenic pulmonary edema.
    Bixby M
    Nursing; 2005 May; 35(5):56-60; quiz 60-1. PubMed ID: 15879973
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 33. Critical review and recommendations for nesiritide use in the emergency department.
    Collins SP; Hinckley WR; Storrow AB
    J Emerg Med; 2005 Oct; 29(3):317-29. PubMed ID: 16183453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality and morbidity of non-systolic heart failure treated with angiotensin-converting enzyme inhibitors: a propensity-adjusted case-control study.
    Gomez-Soto FM; Romero SP; Bernal JA; Escobar MA; Puerto JL; Andrey JL; Almenara J; Gomez F
    Int J Cardiol; 2010 Mar; 139(3):276-82. PubMed ID: 19064293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
    Heywood JT; Khan TA
    Rev Cardiovasc Med; 2007; 8 Suppl 5():S22-9. PubMed ID: 18192950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
    Kazi D; Deswal A
    Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 38. Advances in the treatment of heart failure with a preserved ejection fraction.
    Das A; Abraham S; Deswal A
    Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Warning on diuretic use.
    Grundtvig M; Westheim A; Hole T; Flønaes B; Gullestad L;
    J Am Coll Cardiol; 2010 Jun; 55(23):2609-10; author reply 2610. PubMed ID: 20513605
    [No Abstract]   [Full Text] [Related]  

  • 40. The year in heart failure.
    Tang WH; Francis GS
    J Am Coll Cardiol; 2005 Dec; 46(11):2125-33. PubMed ID: 16325052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.